Table 2.
Treatment Group Comparisons of Change in Visual Acuity and Central Subfield Thickness from Baseline to 1 Year
| Baseline VA 20/50 or Worse (Letter Score <69) | Baseline CST ≥400 microns | Baseline CST <400 microns |
|---|---|---|
| Adjusted Differences in Mean Change (95% CI)* | ||
| A vs. B | (N= 61 vs 61) | (N= 40 vs 39) |
| VA (Letter Score) | 8.1 (CI: 4.9, 11.3) | 5.7 (CI: 1.8, 9.7) |
| VA AUC† (Letter Score) | 4.8 (CI: 2.4, 7.1) | 3.5 (CI: 0.6, 6.4) |
| CST (microns) | −123 (CI: −155, −91) | −31 (CI: −70, 8) |
| A vs. R | (N= 61 vs 50) | (N= 40 vs 49) |
| VA (Letter Score) | 4.5 (CI: 1.2, 7.8) | 4.7 (CI: 0.9, 8.4) |
| VA AUC† (Letter Score) | 2.8 (CI: 0.3, 5.2) | 3.7 (CI: 1.0, 6.5) |
| CST (microns) | −24 (CI: −57, 10) | −7 (CI: −45, 30) |
| R vs. B | (N= 50 vs 61) | (N= 49 vs 39) |
| VA (Letter Score) | 3.6 (CI: 0.3, 7.0) | 1.1 (CI: −2.7, 4.8) |
| VA AUC† (Letter Score) | 2.0 (CI: −0.5, 4.4) | −0.2 (CI: −3.0, 2.5) |
| CST (microns) | −99 (CI: −133, −66) | −24 (CI: −61, 14) |
| Baseline VA 20/32–20/40 (Letter Score 78–69) | Baseline CST ≥400 microns | Baseline CST <400 microns |
| Adjusted Differences in Mean Change (95% CI)* | ||
| A vs. B | (N= 32 vs 30) | (N= 72 vs 73) |
| VA (Letter Score) | 3.7 (CI: −0.8, 8.1) | −1.0 (CI: −3.9, 1.9) |
| VA AUC† (Letter Score) | 3.6 (CI: 0.4, 6.9) | 1.0 (CI: −1.2, 3.1) |
| CST (microns) | −112 (CI: −157, −68) | −32 (CI: −61, −3) |
| A vs. R | (N= 32 vs 43) | (N= 72 vs 59) |
| VA (Letter Score) | 0.2 (CI: −3.8, 4.3) | −0.4 (CI: −3.5, 2.7) |
| VA AUC† (Letter Score) | 1.6 (CI: −1.4, 4.6) | 0.0 (CI: −2.2, 2.3) |
| CST (microns) | −22 (CI: −63, 19) | −20 (CI: −51, 11) |
| R vs. B | (N= 43 vs 30) | (N= 59 vs 73) |
| VA (Letter Score) | 3.4 (CI: −0.8, 7.6) | −0.6 (CI: −3.7, 2.4) |
| VA AUC† (Letter Score) | 2.0 (CI: −1.1, 5.0) | 1.0 (CI: −1.3, 3.2) |
| CST (microns) | −90 (CI: −132, −48) | −12 (CI: −43, 19) |
VA= visual acuity; CST = central subfield thickness; CI = confidence interval; A = aflibercept; B = bevacizumab; R = ranibizumab; AUC = area under curve
CST values usually were translated2 to an equivalent thickness based on a Stratus time domain OCT.
Treatment group comparisons are means from ANCOVA models adjusted for baseline visual acuity (continuous), baseline central subfield thickness (continuous), the three-way interaction of baseline visual acuity (categorical), baseline central subfield thickness (categorical) and treatment and all two-way interactions (categorical).
Baseline central subfield thickness data missing for 2 eyes in the aflibercept group, 2 eyes in the bevacizumab group and 3 eyes in the ranibizumab.
One-year central subfield thickness data missing for 1 eye in the aflibercept group, 1 eye in the bevacizumab group and 2 eyes in the ranibizumab.
One-year visit data unavailable for 16 eyes in the aflibercept group, 12 eyes in the bevacizumab group, and 12 eyes in the ranibizumab group.
Weighted average based on total area under the curve divided by number of days.